Nivolumab plus ipilimumab in non-small-cell lung cancer

Juwon Kim, Sang W. Shin

    Research output: Contribution to journalArticlepeer-review

    1 Citation (Scopus)
    Original languageEnglish
    Pages (from-to)874
    Number of pages1
    JournalNew England Journal of Medicine
    Issue number9
    Publication statusPublished - 2020 Feb 27

    Bibliographical note

    Funding Information:
    Dr. Bersanelli reports receiving research funds from Roche, Pfizer, Seqirus, AstraZeneca, Bristol-Myers Squibb, Novartis, and Sanofi and consulting and speaking fees from Bristol-Myers Squibb, Novartis, and Pfizer; Dr. Tiseo, receiving consulting and speaking fees from AstraZeneca, Pfizer, Eli Lilly, Bristol-Myers Squibb, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, and Pierre Fabre and research grants from AstraZeneca and Boehringer Ingelheim; and Dr. Banna, receiving consulting and speaking fees from Janssen-Cilag, Boehringer Ingelheim, Roche, MSD, and AstraZeneca. No other potential conflict of interest relevant to this letter was reported.

    ASJC Scopus subject areas

    • General Medicine

    Cite this